Where to Purchase Viagra Today? generic viagra online and Today all men suffering from erectile dysfunction and looking for Viagra have a number of options or rather choices to make: buy original Viagra or its generic bioequivalent; buy the chosen medication at a local pharmacy or visit some online one.

Ad Header



The Pulse of the Pharmaceutical Industry

PAREXEL International Expands Model-Based Drug Development Offering

Written by: | support@biospace.com | Dated: Wednesday, July 8th, 2015

BOSTON, July 9, 2015— PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced expanded services and capabilities in model-based drug development (MBDD) through their Quantitative Clinical Development (QCD) group. The PAREXEL QCD team also offers leadership in all strategic and quantitative aspects of clinical pharmacology for biopharmaceutical companies to help expedite drug development, minimize risk, and support regulatory approval processes.

Leveraging mathematical models for a quantitative analysis of the relationship between drugs, disease and patients, modeling and simulation can predict a drug’s benefits and adverse effects in a patient population prior to conducting a clinical trial. MBDD can improve the efficiency of clinical development by providing quantitative justification for trial design, dose selection, and decisions during trial execution. In addition, quantitative clinical pharmacology throughout the lifecycle of a drug candidate supports high quality regulatory packages to help secure regulatory approval.

“The biopharmaceutical landscape continues to show dramatic change, putting companies under increasing pressure to deliver on their pipeline, to identify more effective means of picking the ‘winners’ and efficiently developing these medicines under financial constraints. In addition, regulatory authorities around the world have increasingly accepted model-based techniques as a standard component of new drug applications,” said Frank Hoke, PhD, Vice President of QCD, PAREXEL. “Our goal is to reduce risk along the drug development continuum – for drug developers and for patients – while helping companies make sound investment decisions and accelerating their drug’s journey to market.”

PAREXEL’s Quantitative Clinical Development, one of the largest groups in the industry providing modeling and simulation, is led by Dr. Hoke and supported by a dedicated team of more than 30 scientists with an aggregate of 400+ years of combined clinical development experience. Dr. Hoke and a number of colleagues joined PAREXEL from GlaxoSmithKline’s Clinical Pharmacology Modeling and Simulation department.

For more information about PAREXEL’s QCD modeling and simulation and quantitative clinical pharmacology services, visit PAREXEL.com/solutions/clinical-research/quantitative-clinical-development.

Help employers find you! Check out all the jobs and post your resume.

Source: BioSpace Featured News

Leave a Reply

Be the First to Comment!


Ad Right Top


Extensive pharmaceutical business Dec15cover

and marketing intelligence. If you would like to purchase a back issue, please contact our customer service department at MDAD@kmpsgroup.com, or call 800-869-6882.

December 2015 Focus: Ad Agency Roundtable


Ad Right Bottom

Marketing Communications Directory

Marketing Communications Directory

Healthcare Communications Agencies & Marketing Services Directory

Contract Research Directory

Contract Research Directory

Qualified Clinical Research Organizations Directory

Main Navigation
Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.